Company intelligence / Profile preview
Entheos Labs
Boston, Massachusetts, United Statesentheoslabs.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Entheos Labs develops novel medicines derived from underexplored psychedelics, aiming to address unmet needs in mental health. Their lead program, ET–01, and broader R&D efforts are at the preclinical or early clinical stage. The company collaborates with leading hospitals and universities for research into neuroplasticity, ethnopharmacology, neuroimaging, and drug development. They have raised over $3.5 million since their founding in Boston in 2022.
- Therapeutic areas
- Psychiatry
- Modalities
- New chemical entities derived from psychedelic compounds and plantsPsychedelic-based therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with leading hospitals/universities; specific partners not named but includes Massachusetts General Hospital researchers/advisors.
Beyond the preview
Go deeper on Entheos Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Entheos Labs.